Literature DB >> 6798611

Effects of selected opioid agonists and antagonists on DMT- and LSD-25-induced disruption of food-rewarded bar pressing behavior in the rat.

D M Ruffing, E F Domino.   

Abstract

Several opioid agonists and antagonists interact with N,N-dimethyltryptamine (DMT) and lysergic acid diethylamide-25 (LSD) in adult male Holtzman rats trained on a positive reinforcement, fixed ratio 4 (FR4) behavioral schedule, i.e., a reward of 0.01 ml sugar-sweetened milk was earned on every fourth bar press. DMT (3.2 and 10.0 mg/kg) and LSD (0.1 mg/kg) given IP with 0.9% NaCl pretreatment, disrupted food-rewarded FR4 bar pressing. Animals were pretreated IP (10--15 min) with predetermined, behaviorally noneffective doses of morphine, methadone, naltrexone, and the (+)- and (-)-enantiomers of naloxone prior to receiving DMT or LSD. Dose-dependent effects were shown with opioid agonist pretreatment. Morphine (0.32--1.0 mg/kg) and methadone (0.32 mg/kg) significantly antagonized the bar pressing disruption induced by DMT and LSD. Larger doses of morphine (3.2 mg/kg) and methadone (1.0--3.2 mg/kg) potentiated only LSD-induced effects, with no effect on DMT-treated groups. The opioid antagonists (-)-naloxone and naltrexone potentiated the disruption of bar pressing induced by DMT and LSD. Failure of (+)-naloxone to potentiate the DMT effects was attributed to a stereo-specific opioid antagonist effect of (-)-naloxone.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6798611     DOI: 10.1007/BF00432428

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  28 in total

1.  Behavioral effects of LSD in the cat: proposal of an animal behavior model for studying the actions of hallucinogenic drugs.

Authors:  B L Jacobs; M E Trulson; W C Stern
Journal:  Brain Res       Date:  1977-08-26       Impact factor: 3.252

2.  Opium as a tranquilizer.

Authors:  E T CARLSON; M M SIMPSON
Journal:  Am J Psychiatry       Date:  1963-08       Impact factor: 18.112

3.  Antiemetic activity of D-lysergic acid diethylamide.

Authors:  B N DHAWAN; G P GUPTA
Journal:  J Pharmacol Exp Ther       Date:  1961-07       Impact factor: 4.030

4.  Blockade of LSD-25 pyrexia by morphine.

Authors:  B N DHAWAN
Journal:  Arch Int Pharmacodyn Ther       Date:  1960-09-01

5.  LSD as an agonist and antagonist at central dopamine receptors.

Authors:  K Von Hungen; S Roberts; D F Hill
Journal:  Nature       Date:  1974-12-13       Impact factor: 49.962

6.  Stereospecific, dose-dependent antagonism by naloxone of non-opiate behavior in mice.

Authors:  Y F Jacquet
Journal:  Pharmacol Biochem Behav       Date:  1980-10       Impact factor: 3.533

7.  Naloxone potentiates the disruptive effects of mescaline on operant responding in the rat.

Authors:  R L Commissaris; K E Moore; R H Rech
Journal:  Pharmacol Biochem Behav       Date:  1980-10       Impact factor: 3.533

8.  Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors.

Authors:  H Y Meltzer; R G Fessler; M Simonovic; J Doherty; V S Fang
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

9.  Interactions of partial LSD analogs with behavioral disrupting effects of LSD and DMT in the rat.

Authors:  B Kovacic; L J Wang Lu; D Ruffing; E F Domino
Journal:  Eur J Pharmacol       Date:  1978-01-01       Impact factor: 4.432

10.  Interaction between narcotic antagonist (naloxone) and lysergic acid diethylamide (LSD) in the rat.

Authors:  A P Fertziger; R Fischer
Journal:  Psychopharmacology (Berl)       Date:  1977-11-15       Impact factor: 4.530

View more
  2 in total

1.  Potentiation of disruptive effects of dextromethorphan by naloxone on fixed-interval performance in rats.

Authors:  T Taşkin
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.